UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) March 16, 2010
The Ensign Group, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-33757
|
|
33-0861263 |
|
|
|
|
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.) |
|
|
|
27101 Puerta Real, Suite 450, Mission Viejo, CA
|
|
92691 |
|
|
|
(Address of principal executive offices)
|
|
(Zip Code) |
Registrants telephone number, including area code (949) 487-9500
|
Not Applicable
|
(Former name or former address, if changed since last report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of
Certain Officers; Compensatory Arrangements of Certain Officers.
Executive Incentive Program
On March 11, 2010, our compensation committee approved the performance criteria for 2010 for
our executive incentive program. Certain of our executive officers, including our Chief Executive
Officer (CEO), Executive Vice President and Secretary, and Chief Financial Officer (CFO) will
participate in our executive incentive program in 2010. The monetary component of the formula
established by the compensation committee for our executive incentive program is based upon annual
income before provision for income taxes. The program also includes a
subjective Quality adjustment for the
clinical performance of the Companys operating subsidiaries, as well as a discretionary clawback
provision that allows incentive payments to be recouped from executive officers if certain types of
subsequent events result in a restatement or otherwise diminish the performance metrics upon which
prior incentive calculations were based.
In or near the first quarter of 2011, our compensation committee will subjectively allocate
the bonus pool among the individual executives that participate in the plan based upon the
recommendations of our CEO and the compensation committees perceptions of each participating
executives contributions to both our clinical and financial performance during the preceding year,
and value to the organization going forward. The financial measure that our compensation committee
considers is our annual income before provision for income taxes. The clinical measures that our
compensation committee considers include our success in achieving positive survey results and the
extent of positive patient and resident feedback, among other factors. Our compensation committee
also reviews and considers feedback from other employees regarding the executives performance. Our
compensation committee exercises discretion in the allocation of the bonus pool among the
individual executives and has, at times, awarded bonuses that, collectively, were less than the
bonus pool resulting from the predetermined formula.
Cash Bonuses for the Presidents of our Portfolio Companies
On
March 11, 2010, management established the bonus criteria for each of the presidents of our
portfolio companies. Presidents of our portfolio companies may earn cash bonuses by meeting target
clinical and financial measurements for their respective portfolio companies. They are eligible to
earn short-term cash bonuses, the amount of which is established pursuant to a formula based upon
their respective portfolio companys income before provision for income taxes. The amount of these
bonuses increases for each tier of the target milestones, and such bonuses are not subject to a
cap. Each year the formula is adjusted, so it becomes increasingly more difficult for presidents to
earn the same bonus each year. The bonuses are determined based upon managements perception of
each presidents contribution to the achievement of clinical and financial objectives during the
preceding year at their portfolio company, and the value to the portfolio company going forward.
The financial objective that we consider is the presidents contribution to his portfolio companys
annual income before provision for income taxes. The clinical measures that management considers
include factors such as the presidents contribution to achieving positive survey results, and
positive patient and resident feedback. Management also reviews and considers feedback from other
employees regarding the presidents performance.